Quarterly report pursuant to Section 13 or 15(d)

Note 16 - Segments - Segment Information (Details)

v3.8.0.1
Note 16 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Tc 99m tilmanocept sales revenue $ 17,601 $ 30,800  
Tc99m tilmanocept license revenue 1,295,625 100,000 1,795,625  
Grant and other revenue 223,669 510,974 1,315,298 2,113,420  
Revenues 223,669 1,824,200 1,415,298 3,939,845  
Cost of goods sold, excluding depreciation and amortization 2,889 5,185  
Research and development expenses, excluding depreciation and amortization 874,547 919,441 2,765,695 5,010,923  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [1] 1,684,381 1,721,831 8,809,070 5,573,624  
Depreciation, Depletion and Amortization, Nonproduction [2] 50,326 89,849 197,655 258,999  
Loss from operations (3) [3] (2,385,585) (909,810) (10,357,122) (6,908,886)  
Other income (4) 69,071 (851,637) (1,061,190) 1,649,106  
Income tax benefit 775,750 0 3,861,156  
Net loss from continuing operations (1,540,764) (1,761,447) (7,557,156) (5,259,780)  
Income from discontinued operations, net of tax 5,399 1,701,911 (332,838) (5,167,312)  
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax 145,877 86,894,000  
Net income (1,389,488) (59,536) 79,004,006 (10,427,092)  
Total assets, net of depreciation and amortization 22,605,707   22,605,707   $ 12,461,676
Capital expenditures 23,247 31,417 1,847  
Other expenses (4) [4]   (851,637)   1,664,265  
Equity in loss of R-NAV, LLC (15,159)  
UNITED STATES          
Tc 99m tilmanocept sales revenue  
Total assets, net of depreciation and amortization 22,521,506 11,040,679 22,521,506 11,040,679  
Non-US [Member]          
Tc 99m tilmanocept sales revenue 17,601 30,800  
Total assets, net of depreciation and amortization 84,201 148,921 84,201 148,921  
Diagnostics Segment [Member]          
Tc99m tilmanocept license revenue 1,295,625 100,000 1,795,625  
Grant and other revenue 210,479 500,628 1,200,216 2,051,622  
Revenues 210,479 1,813,854 1,300,216 3,878,047  
Cost of goods sold, excluding depreciation and amortization 2,889 5,185  
Research and development expenses, excluding depreciation and amortization 734,539 671,777 2,255,842 4,410,133  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [1]  
Depreciation, Depletion and Amortization, Nonproduction [2]  
Loss from operations (3) [3] (524,060) 1,139,188 (955,626) (537,271)  
Other income (4)      
Income tax benefit 175,496   323,149    
Net loss from continuing operations (348,564) 1,139,188 (632,477) (537,271)  
Income from discontinued operations, net of tax 5,399 1,701,911 (332,838) (5,167,312)  
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax 145,877   86,894,000    
Net income (197,288) 2,841,099 85,928,685 (5,704,583)  
Capital expenditures  
Other expenses (4) [4]      
Equity in loss of R-NAV, LLC        
Diagnostics Segment [Member] | UNITED STATES          
Tc 99m tilmanocept sales revenue  
Total assets, net of depreciation and amortization 14,675,489 4,950,756 14,675,489 4,950,756  
Diagnostics Segment [Member] | Non-US [Member]          
Tc 99m tilmanocept sales revenue 17,601 30,800  
Total assets, net of depreciation and amortization 82,334 148,224 82,334 148,224  
Therapeutics Segment [Member]          
Tc99m tilmanocept license revenue  
Grant and other revenue 13,190 10,346 115,082 61,798  
Revenues 13,190 10,346 115,082 61,798  
Cost of goods sold, excluding depreciation and amortization  
Research and development expenses, excluding depreciation and amortization 140,008 247,664 509,853 600,790  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [1] 13,359 27,758 19,342 31,590  
Depreciation, Depletion and Amortization, Nonproduction [2]  
Loss from operations (3) [3] (140,177) (265,076) (414,113) (570,582)  
Other income (4)      
Income tax benefit 46,942   140,034    
Net loss from continuing operations (93,235) (265,076) (274,079) (570,582)  
Income from discontinued operations, net of tax  
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax      
Net income (93,235) (265,076) (274,079) (570,582)  
Capital expenditures  
Other expenses (4) [4]      
Equity in loss of R-NAV, LLC        
Therapeutics Segment [Member] | UNITED STATES          
Tc 99m tilmanocept sales revenue  
Total assets, net of depreciation and amortization 10,591 9,356 10,591 9,356  
Therapeutics Segment [Member] | Non-US [Member]          
Tc 99m tilmanocept sales revenue  
Total assets, net of depreciation and amortization  
Corporate Segment [Member]          
Tc99m tilmanocept license revenue  
Grant and other revenue  
Revenues  
Cost of goods sold, excluding depreciation and amortization  
Research and development expenses, excluding depreciation and amortization  
Selling, general and administrative expenses, excluding depreciation and amortization (1) [1] 1,671,022 1,694,073 8,789,728 5,542,034  
Depreciation, Depletion and Amortization, Nonproduction [2] 50,326 89,849 197,655 258,999  
Loss from operations (3) [3] (1,721,348) (1,783,922) (8,987,383) (5,801,033)  
Other income (4) 69,071   (1,061,190)    
Income tax benefit 553,312   3,397,972    
Net loss from continuing operations (1,098,965) (2,635,559) (6,650,601) (4,151,927)  
Income from discontinued operations, net of tax  
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax      
Net income (1,098,965) (2,635,559) (6,650,601) (4,151,927)  
Capital expenditures 23,247 31,417 1,847  
Other expenses (4) [4]   (851,637)   1,664,265  
Equity in loss of R-NAV, LLC       (15,159)  
Corporate Segment [Member] | UNITED STATES          
Tc 99m tilmanocept sales revenue  
Total assets, net of depreciation and amortization 7,835,426 6,080,567 7,835,426 6,080,567  
Corporate Segment [Member] | Non-US [Member]          
Tc 99m tilmanocept sales revenue  
Total assets, net of depreciation and amortization $ 1,867 $ 697 $ 1,867 $ 697  
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($50,326 and $89,849 for the three-month periods ended September 30, 2017 and 2016 and $197,655 and $258,999 for the nine-month periods ended September 30, 2017 and 2016, respectively).
[3] Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[4] Amounts consist primarily of changes in fair value of financial instruments and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.